Richard Straube
Chief Tech/Sci/R&D Officer at SOLIGENIX, INC.
Net worth: 228 $ as of 2024-04-29
Profile
Richard C.
Straube is currently the Chief Medical Officer & Senior Vice President at Soligenix, Inc. He previously held positions as Senior Director-Clinical Research & Immunology at Centocor, Inc. from 1988 to 1993, Director-Medical Affairs at T Cell Sciences, Inc. from 1993 to 1995, Director-Clinical Investigations at Ohmeda, Inc. from 1995 to 1997, Chief Scientific Officer, Executive VP-R&D at INO Therapeutics LLC from 1998 to 2007, Principal at Inomax LLC (Florida), and Chief Medical Officer at Stealth BioTherapeutics Corp.
from 2009 to 2014.
He also served as a Faculty Member at the University of California San Diego.
Dr. Straube holds a doctorate degree from The University of Chicago and a graduate degree from the London School of Hygiene & Tropical Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
SOLIGENIX, INC.
0.00% | 2024-04-09 | 534 ( 0.00% ) | 228 $ | 2024-04-29 |
Richard Straube active positions
Companies | Position | Start |
---|---|---|
SOLIGENIX, INC. | Chief Tech/Sci/R&D Officer | 2014-01-05 |
Former positions of Richard Straube
Companies | Position | End |
---|---|---|
STEALTH BIOTHERAPEUTICS CORP | Chief Tech/Sci/R&D Officer | 2014-01-05 |
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2008-12-31 |
INO Therapeutics LLC
INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ. | Chief Tech/Sci/R&D Officer | 2006-12-31 |
Ohmeda, Inc. | Corporate Officer/Principal | 1997-01-01 |
T Cell Sciences, Inc. | Chief Tech/Sci/R&D Officer | 1994-12-31 |
Training of Richard Straube
The University of Chicago | Doctorate Degree |
London School of Hygiene & Tropical Medicine | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SOLIGENIX, INC. | Health Technology |
Private companies | 7 |
---|---|
Critical Biologics Corp.
Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA. | Health Technology |
T Cell Sciences, Inc. | Health Technology |
Centocor, Inc.
Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Inomax LLC (Florida)
Inomax LLC (Florida) Investment ManagersFinance Inomax LLC is an American venture capital company. | Finance |
INO Therapeutics LLC
INO Therapeutics LLC Pharmaceuticals: MajorHealth Technology INO Therapeutics LLC engages in the development of pharmaceutical drugs. The company is headquartered in Hampton, NJ. | Health Technology |
Ohmeda, Inc. | |
Stealth BioTherapeutics Corp.
Stealth BioTherapeutics Corp. BiotechnologyHealth Technology Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in Needham, MA. | Health Technology |
- Stock Market
- Insiders
- Richard Straube